𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers

✍ Scribed by Akiyo Horio; Takashi Fujita; Hironori Hayashi; Masaya Hattori; Naoto Kondou; Mai Yamada; Eri Adachi; Aya Ushio; Naomi Gondou; Aiko Sueta; Yasushi Yatabe; Hiroji Iwata

Book ID
113057621
Publisher
Springer
Year
2011
Tongue
English
Weight
505 KB
Volume
17
Category
Article
ISSN
1341-9625

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Adjuvant trastuzumab with chemotherapy i
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer
✍ Heather L. McArthur; Kathleen M. Mahoney; Patrick G. Morris; Sujata Patil; Linds πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 243 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: Several large, randomized trials established the benefits of adjuvant trastuzumab with chemotherapy. However, the benefit for women with small, node‐negative HER2‐positive (HER2+) disease is unknown, as these patients were largely excluded from these trials. Therefore, a